NASDAQ:FBLG

Fibrobiologics Stock News

Healthcare > Biotechnology

Buy FBLG

*Your capital is at risk

$1.07

+0.0200 (+1.90%)

At Close: Jun 03, 2026

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

08:30am, Wednesday, 31'st Dec 2025

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the d

FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Down 42.8% in December

04:20am, Saturday, 27'th Dec 2025

FibroBiologics Inc. (NASDAQ: FBLG - Get Free Report) saw a significant drop in short interest in December. As of December 15th, there was short interest totaling 795,335 shares, a drop of 42.8% from t

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

04:05pm, Tuesday, 16'th Dec 2025

HOUSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

08:00am, Monday, 15'th Dec 2025

HOUSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending

FibroBiologics (NASDAQ:FBLG) Trading 4.8% Higher – What’s Next?

02:41am, Friday, 12'th Dec 2025

FibroBiologics Inc. (NASDAQ: FBLG - Get Free Report)'s stock price shot up 4.8% during trading on Thursday. The company traded as high as $0.3649 and last traded at $0.3477. 1,486,145 shares were trad

FibroBiologics Files New Patent For Fibroblast Tech To Advance Deeper Into Orthopedics

11:36am, Wednesday, 10'th Dec 2025

On Wednesday, FibroBiologics, Inc. (NASDAQ: FBLG) submitted a new patent application with the U.S. Patent and Trademark Office (USPTO).

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

08:30am, Wednesday, 10'th Dec 2025

HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending

FibroBiologics Announces Payoff of Outstanding Debt

08:30am, Wednesday, 26'th Nov 2025

Repayment of convertible promissory notes strengthens balance sheet and eliminates further dilution from conversions Repayment of convertible promissory notes strengthens balance sheet and eliminates

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

04:05pm, Tuesday, 25'th Nov 2025

HOUSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

09:00am, Monday, 24'th Nov 2025

HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

08:00am, Thursday, 20'th Nov 2025

HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the d

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by